Kansas City, MONCT07751029Now EnrollingIRB Ready

Menopause Clinical Trial in Kansas City, MO

Access cutting-edge menopause treatment through this clinical trial at a research site in Kansas City. Study-provided care at no cost to qualified participants.

Sponsored by Spectrum Clinical Research, LLC

Quick Self-Assessment

See if you qualify for this Kansas City location

Preparing your pre-screening questions…

Expert Care in Kansas City

Access menopause specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related menopause treatment provided free

Apply for This Kansas City Location

Check if you qualify for this menopause clinical trial in Kansas City, MO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Kansas City

    Convenient for MO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Kansas City site if eligible
  4. 4Begin participation

About This Menopause Study in Kansas City

This proof-of-concept, open-label, single-arm study is designed to evaluate the effects of daily consumption of Haelan 951, a fermented soy conventional food product, on self-reported menopausal vasomotor symptoms, sleep quality, and health-related quality of life in peri- and postmenopausal women. The study will collect descriptive data on participant-reported outcomes over the study period to assess the feasibility and potential effects of Haelan 951 in supporting menopausal wellness. The study is not intended to evaluate the treatment, prevention, or cure of any disease.

Sponsor: Spectrum Clinical Research, LLC

Who Can Participate

Inclusion Criteria

Female sex assigned at birth, ages 45-65 years inclusive at the time of consent.
Post-menopausal (≥12 consecutive months amenorrhea, STRAW+10 stage +1) OR peri-menopausal (STRAW+10 stages -2 or -1) at consent. PI to confirm staging at Screening.
Self-reported vasomotor symptoms ≥3 months' duration prior to Screening, averaging ≥4 episodes per 24-hour period over the 7 days prior to Screening.
Willing and able to consume the investigational product as directed (30 mL twice daily, empty stomach, 30 days).
Willing and able to complete daily eCOA entries in the study application and to wear the study wearable throughout the Treatment period.
Possession of (or willingness to use) a personal smartphone running iOS 16+ or Android 12+, with reliable daily internet access.
Resident of the Kansas City metropolitan area \[30- 45 mile radius\] and able to travel to Spectrum Clinical Research for a single onsite Participant Onboarding Visit.
Able to read, understand, and provide written informed consent in English at approximately an 8th-grade reading level.
Willing to abstain from initiation of any new HRT, menopause-related supplement, or other menopause-related therapeutic intervention for the study duration.

Exclusion Criteria

Pre-menopausal status (STRAW+10 stage -3 or earlier).
Current pregnancy, planning pregnancy during the study, or breastfeeding.
Current use of any systemic or topical HRT. Required wash-out prior to Day 1: 30 days systemic and 30 days topical/local, aligned with the Screening period and the 30-day study duration; the PI may extend for an individual on documented clinical rationale per ICH E6(R3) 4.2.1.
Current use of any menopause-related dietary supplement within 30 days prior to Day 1, unless on a stable regimen ≥3 months and willing to maintain it unchanged (documented in medical history).
Known soy allergy or hypersensitivity to any component of Haelan 951 (Purified Water, Organic Cultured Soy Powder, Yeast, Salt).
History of estrogen- or progesterone-receptor-positive breast cancer; active malignancy of any type; or current systemic chemotherapy, immunotherapy, or radiation therapy.
Heavy alcohol use (≥3 alcoholic beverages/day on average, per NIAAA definitions).
Major surgical procedure or hospitalization within 90 days prior to Screening, or any unresolved condition that the PI judges would compromise safety or interpretation of endpoints.
Documented uncontrolled or unstable medical condition (e.g., uncontrolled cardiovascular disease; CKD stage 3b or worse; moderate-to-severe hepatic impairment; active autoimmune disease on systemic immunosuppression), established from medical history and PI clinical assessment.
Current use of medications with documented potential for clinically significant interaction with soy-derived foods (thyroid replacement unless dose-stable ≥6 weeks with 4-hour separation; oral anticoagulants on non-stable dose; MAOIs; tamoxifen or other hormone-modulating cancer therapies).
Current or recent (within 30 days) participation in another interventional clinical study.
Inability to provide informed consent (cognitive impairment, language barrier - materials are English-only - or other reason per PI judgment).
Other reasons judged by the PI, with documented rationale per ICH E6(R3) 4.2.1, to compromise safety, well-being, or scientific validity.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Kansas City?

Yes, this clinical trial (NCT07751029) has an active research site in Kansas City, MO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Menopause Treatment Options in Kansas City, MO

If you're searching for menopause treatment options in Kansas City, MO, this clinical trial (NCT07751029) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Kansas City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced menopause specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all menopause clinical trials near you to find additional studies recruiting in your area.

More Menopause Trials in Kansas City, MO

See all menopause clinical trials recruiting in Kansas City — not just this study.

Browse Menopause Trials in Kansas City →

Browse More Trials by Condition

Menopause TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Kansas City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Kansas City, MO